Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapeutics symbols : Hznp save search
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
Published: 2023-11-14 (Crawled : 12:00) - globenewswire.com
LRMR | $6.46 0.0% 220K
|
Health Technology
|
| O: 0.42%
H: 16.25%
C: 6.67%
therapeutics financial results
Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors
Published: 2023-10-03 (Crawled : 20:00) - globenewswire.com
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -2.07%
H: 0.19%
C: -0.07%
LRMR | $6.46 0.0% 220K
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: -2.42%
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.0%
H: 0.03%
C: 0.02%
therapeutics
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023
Published: 2023-10-02 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.1%
H: 0.13%
C: 0.11%
uplizna therapeutics
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata
Published: 2023-09-13 (Crawled : 13:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.23%
H: 0.28%
C: 0.14%
adx-914 trial therapeutics
AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION
Published: 2023-09-01 (Crawled : 13:30) - prnewswire.com
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 2.63%
H: 0.0%
C: -0.35%
BGNE | $144.0 3.61% 3.48% 220K
|
Health Technology
|
| O: 0.36%
H: 2.44%
C: 0.3%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 0.91%
H: 0.14%
C: -0.76%
resolve acquisition therapeutics
Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy Groups
Published: 2023-08-23 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.2%
H: 1.37%
C: 1.01%
rare disease therapeutics
Horizon Therapeutics plc to Release Second-Quarter 2023 Financial Results on Aug. 8, 2023
Published: 2023-07-17 (Crawled : 12:20) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.25%
H: 0.32%
C: -0.19%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -0.25%
H: 0.76%
C: 0.43%
therapeutics financial results
Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
Published: 2023-06-22 (Crawled : 12:20) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.25%
H: 0.75%
C: 0.04%
tepezza disease active japan positive treatment thyroid topline eye trial therapeutics
Horizon Therapeutics plc Announces Data from the TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial to be Presented at the Upcoming Endocrine Society (ENDO) Annual Meeting
Published: 2023-06-05 (Crawled : 15:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.0%
H: 0.15%
C: -0.26%
tepezza endocrine meeting trial therapeutics
Horizon Therapeutics plc Announces Presentation of Data that Advances the Understanding of Rheumatic Diseases at the 2023 EULAR European Congress of Rheumatology
Published: 2023-05-23 (Crawled : 13:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.33%
H: 0.24%
C: -0.79%
presentation therapeutics
Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by U.S. Patient Advocacy Groups
Published: 2023-05-09 (Crawled : 13:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.13%
H: 0.61%
C: 0.15%
therapeutics
Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results
Published: 2023-05-03 (Crawled : 12:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.86%
H: 0.63%
C: 0.0%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 0.0%
H: 0.14%
C: -2.82%
therapeutics financial results
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis
Published: 2023-05-02 (Crawled : 16:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.04%
H: 0.04%
C: -0.21%
lupus treatment trial therapeutics phase 2
Horizon Therapeutics plc Ranks First in Patient Centricity and Integrity by Patient Advocacy Groups According to New PatientView Survey
Published: 2023-05-02 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.04%
H: 0.04%
C: -0.21%
therapeutics
Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
Published: 2023-05-01 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.25%
H: 0.5%
C: 0.46%
tepezza disease japan score thyroid eye trial therapeutics
Horizon Therapeutics plc Announces UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the 2023 American Academy of Neurology (AAN) Annual Meeting
Published: 2023-04-20 (Crawled : 13:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.04%
H: 0.16%
C: -0.13%
uplizna meeting therapeutics
Horizon Therapeutics plc to Release First-Quarter 2023 Financial Results on May 3, 2023
Published: 2023-04-14 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.25%
H: 1.1%
C: 0.54%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -0.33%
H: 0.45%
C: -0.25%
therapeutics financial results
Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for TEPEZZA® (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease Activity or Duration
Published: 2023-04-14 (Crawled : 13:20) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.25%
H: 1.1%
C: 0.54%
tepezza fda disease approval update thyroid eye therapeutics
Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
Published: 2023-04-10 (Crawled : 13:20) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.26%
H: 0.72%
C: 0.28%
tepezza disease score positive thyroid topline eye trial therapeutics
Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2022 Financial Results
Published: 2023-03-01 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.0%
H: 0.91%
C: 0.78%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -0.56%
H: 2.63%
C: 2.53%
therapeutics financial results
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.